Aviir (Irvine, CA) a commercial-stage diagnostic company focused on pharmacogenomic and genetic tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders, closed a $10M Series E financing. Participants include Merck Global Health Innovation, Bay City Capital, Aberdare Ventures and New Leaf Venture Partners.

Portola Pharmaceuticals (South San Francisco, CA) a clinical-stage small moelcule company focused on acute and chronic cardiovascular and autoimmune and inflammatory diseases, closed an $89M Series E financing. Participants included Temasek, Eastern Capital Limited, D.E. Shaw, Adage Capital Management, BBT Capital Management, Janus Capital Group and Pac-Link BioVentures.

AuraSense Therapeutics (Evanston, IL) a development-stage biotechnology company focused on nucleic acid constructs for heart disease, cancer, skin conditions and bacterial infection, closed a $4.5M Series B financing. Participants include Abbott Biotech Ventures.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on development of adaptable non-absorbed polymeric drugs to for congestive heart failure, chronic kidney disease, end stage renal disease and hypertension, closed a $36M Series B financing. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.
Thanx for your patience as we [...]

Milestone Pharmaceuticals (Canada) a development-stage pharmaceutical company focused on small molecules for atrial arrhythmias and angina, closed a $13M Series B financing. Participants include Pappas Ventures, GO Capital, Fonds de solidarité FTQ, iNovia Healthcare Ventures and Fonds Bio-Innovation.
The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach [...]

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on cardiovascular and renal disorders, closed a $36M Series B financing, bringing the total round to $53M. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.

NextWave Pharmaceuticals (Cupertino, CA) a clinical-stage specialty pharmaceutical focused on cardiovascular and CNS diseases, closed a $45M Series C financing. Participants include Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures.

Omthera Pharmaceuticals (Bedminster, NJ) a clinical-stage specialty biopharma company focused on an Omega-3 fatty acid containing DHA and EPA as a therapy for dyslipidemia, closed a $33.9M Series B financing. Participants include New Enterprise Associates and Sofinnova Ventures.

Prolong Pharmaceuticals (South Plainfield, NJ) a near clinical-stage biopharmaceuticals company focused sickle cell anemia, stroke and diabetic induced ischemia, closed a $30M Series C financing. Participants were not identified.

Aires Pharmaceuticals (San Diego, CA) a clinical-stage pharmaceutical company focused on small molecule combination therapy for the treatment of pulmonary arterial hypertension, closed a $20M Series B financing. Participants include MPM Capital and ProQuest Investments.

Capricor (Los Angeles, CA) a development-stage regenerative medicine company focused on stem cell therapies for treatment of cardiac disease, closed a $2M Series A financing. Participants include Broadview Ventures.

Cerenis Therapeutics (France) a clinical-stage biopharmaceutical company focused on dyslipidemia and aortic valve stenosis, closed a $13.6M Series C bring the total round to approximately $68.3M. Participants include IXO Private Equity.

Cardioxyl Pharmaceuticals (Chapel Hill, NC) a clinical-stage small molecule company focused on acute decompensated heart failure, closed a $15M Series C financing. Participants include Aurora Funds and New Enterprise Associates.